These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

523 related articles for article (PubMed ID: 28889393)

  • 1. Epigenetic Treatment Options in Urothelial Carcinoma.
    Pinkerneil M; Hoffmann MJ; Niegisch G
    Methods Mol Biol; 2018; 1655():289-317. PubMed ID: 28889393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic Priming and Development of New Combination Therapy Approaches.
    Meneceur S; Grunewald CM; Niegisch G; Hoffmann MJ
    Methods Mol Biol; 2023; 2684():259-281. PubMed ID: 37410240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic therapy of cancer with histone deacetylase inhibitors.
    Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
    J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone modification therapy of cancer.
    Biancotto C; Frigè G; Minucci S
    Adv Genet; 2010; 70():341-86. PubMed ID: 20920755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic agents in combined anticancer therapy.
    Kejík Z; Jakubek M; Kaplánek R; Králová J; Mikula I; Martásek P; Král V
    Future Med Chem; 2018 May; 10(9):1113-1130. PubMed ID: 29676175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Re-programing Chromatin with a Bifunctional LSD1/HDAC Inhibitor Induces Therapeutic Differentiation in DIPG.
    Anastas JN; Zee BM; Kalin JH; Kim M; Guo R; Alexandrescu S; Blanco MA; Giera S; Gillespie SM; Das J; Wu M; Nocco S; Bonal DM; Nguyen QD; Suva ML; Bernstein BE; Alani R; Golub TR; Cole PA; Filbin MG; Shi Y
    Cancer Cell; 2019 Nov; 36(5):528-544.e10. PubMed ID: 31631026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Manipulating the epigenome for the treatment of urological malignancies.
    O'Rourke CJ; Knabben V; Bolton E; Moran D; Lynch T; Hollywood D; Perry AS
    Pharmacol Ther; 2013 May; 138(2):185-96. PubMed ID: 23353098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic cancer therapy: Proof of concept and remaining challenges.
    Mund C; Lyko F
    Bioessays; 2010 Nov; 32(11):949-57. PubMed ID: 21154865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
    Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
    J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic Regulatory Mechanisms Induced by Resveratrol.
    Fernandes GFS; Silva GDB; Pavan AR; Chiba DE; Chin CM; Dos Santos JL
    Nutrients; 2017 Nov; 9(11):. PubMed ID: 29104258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natural Product Inhibitors of Histone Deacetylases as New Anticancer Agents.
    Hanikoglu A; Hanikoglu F; Ozben T
    Curr Protein Pept Sci; 2018; 19(3):333-340. PubMed ID: 28059044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of histone deacetylase inhibitory prodrugs on epigenetic changes and DNA damage response in tumor and heart of glioblastoma xenograft.
    Tarasenko N; Nudelman A; Rozic G; Cutts SM; Rephaeli A
    Invest New Drugs; 2017 Aug; 35(4):412-426. PubMed ID: 28315153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct monitoring of breast and endometrial cancer cell epigenetic response to DNA methyltransferase and histone deacetylase inhibitors.
    Teixeira SR; Abreu CM; Parkes L; Davies J; Yao S; Sawhney MA; Margarit L; Gonzalez D; Pinto IM; Francis LW; Conlan RS
    Biosens Bioelectron; 2019 Sep; 141():111386. PubMed ID: 31220725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic small molecule modulators of histone and DNA methylation.
    Hauser AT; Robaa D; Jung M
    Curr Opin Chem Biol; 2018 Aug; 45():73-85. PubMed ID: 29579619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transcriptional Selectivity of Epigenetic Therapy in Cancer.
    Sato T; Cesaroni M; Chung W; Panjarian S; Tran A; Madzo J; Okamoto Y; Zhang H; Chen X; Jelinek J; Issa JJ
    Cancer Res; 2017 Jan; 77(2):470-481. PubMed ID: 27879268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic Targets and their Inhibitors in Cancer Therapy.
    Zhao L; Duan YT; Lu P; Zhang ZJ; Zheng XK; Wang JL; Feng WS
    Curr Top Med Chem; 2018; 18(28):2395-2419. PubMed ID: 30582481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone deacetylase inhibitors exert anti-tumor effects on human adherent and stem-like glioma cells.
    Was H; Krol SK; Rotili D; Mai A; Wojtas B; Kaminska B; Maleszewska M
    Clin Epigenetics; 2019 Jan; 11(1):11. PubMed ID: 30654849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Troglitazone inhibits histone deacetylase activity in breast cancer cells.
    Davies GF; Ross AR; Arnason TG; Juurlink BH; Harkness TA
    Cancer Lett; 2010 Feb; 288(2):236-50. PubMed ID: 19699029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Development of novel epigenetic molecular-targeting agents].
    Sowa Y; Sakai T
    Nihon Rinsho; 2015 Aug; 73(8):1263-7. PubMed ID: 26281676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Promises and challenges of anticancer drugs that target the epigenome.
    Verbrugge I; Johnstone RW; Bots M
    Epigenomics; 2011 Oct; 3(5):547-65. PubMed ID: 22126246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.